Our publications on pharmaceutical industry-led access initiatives
We reviewed the initiatives of twenty-one research-based global biopharmaceutical companies to assess their strategies for improving access and the quality of evidence on the impact of their initiatives. Read the article here
We discuss why we believe there is a unique opportunity for the industry, academia, and other global health stakeholders to come together and strengthen institutions for measuring industry-led access-to-medicines (IL-AtM) programs. Read the commentary here
Gilead’s Access Program
Read about the development of the Gilead Access Program here
Background information on voluntary licensing
Read about voluntary licensing in the pharmaceutical sector here
Evaluation of Gilead Access Program 